"An investment in knowledge pays the best interest."


MedX Health Corp.(MDX.V) has received an initial order in excess of $100,000 for its pain-free, non-invasive skin assessment SIAscopy technology for use in Spain through its marketing partnership with OncoTech LLC. In May, 2017, MedX announced that OncoTech, a United States-based company which has built strong business relationships in Spain, Mexico and Colombia, would help MedX establish and grow sales in these Latin countries.

"We are very pleased by this initial order as it is the first step, we believe, in a long-term relationship with OncoTech who have been the driving force in this initiative. We expect momentum to increase as we grow our business in these important markets," said Rob von der Porten, MedX's chief executive officer. "According to research published in the Journal of the Academy of Dermatology, skin cancers in Hispanics have risen more than 20 per cent in the past two decades. Skin cancers are being detected at later stages, which puts this population at greater risk of mortality. MedX's SIAscopy technology should measurably help the early detection of melanoma and other skin cancers, thereby saving lives and reducing the financial burden on health care systems." The company has CE regulatory clearance for SIAscopy within all European countries, including Spain, and MedX has commenced work with OncoTech to secure regulatory clearance in Latin America.

About MedX Health Corp.

MedX, headquartered in Mississauga, Ont., is a leading medical device company focused on skin cancer with its SIAscopy technology. This technology is imbedded in its products Siametrics, Simsys and MoleMate, which MedX manufactures in its ISO 13485-certified facility. MedX also designs, manufactures and distributes quality laser and light therapy technologies for use in numerous medical settings, approved in major jurisdictions, to provide drug-free and non-invasive treatment of tissue damage and pain.